The meta-analysis results from this study are available at dbGAP (accession number phs000930).

Introduction {#sec001}
============

Hypertension is a major risk factor for cardiovascular disease (CVD)\[[@pone.0198166.ref001]\], which in 2015 alone was estimated to cause about 10.7 million deaths worldwide\[[@pone.0198166.ref002]\]. The prevalence of hypertension in the US is \~46% for those of African ancestry compared to \~33% for European ancestry and \~30% for Hispanic ancestry\[[@pone.0198166.ref003]\] based on previous blood pressure (BP) guidelines (The Seventh Report of the Joint National Committee on Prevention)\[[@pone.0198166.ref004]\]. Recently, based on the 2017 American College of Cardiology/ American Heart Association high BP guideline, the overall prevalence of hypertension among US adults is estimated at 45.6%\[[@pone.0198166.ref005]\]. Blood pressure levels are influenced by alcohol consumption independently of adiposity, sodium intake, smoking and socio-economic status\[[@pone.0198166.ref006]\]. Alcohol shows a dose-dependent effect on systolic BP (SBP) after adjusting for environmental confounders\[[@pone.0198166.ref007]\].

Genome-wide association studies (GWAS) have identified more than 400 single nucleotide variants (SNVs) for BP\[[@pone.0198166.ref008]--[@pone.0198166.ref014]\] and about 30 SNVs for alcohol consumption\[[@pone.0198166.ref015]--[@pone.0198166.ref017]\]. However, few studies have explored SNV-alcohol interactions in relation to BP\[[@pone.0198166.ref018], [@pone.0198166.ref019]\], in part due to the large sample sizes required to obtain adequate power\[[@pone.0198166.ref018], [@pone.0198166.ref020]\]. SNVs, which effect differ by level of alcohol consumption, can harbor modest marginal effects and might therefore be missed by standard marginal effects association screening. As previously demonstrated, a joint test of main genetic effect and gene-environmental interaction can have higher power\[[@pone.0198166.ref021]\] to identify such variants.

Within the CHARGE Gene-Lifestyle Interactions Working Group\[[@pone.0198166.ref022], [@pone.0198166.ref023]\], we studied a total of 571,652 adults across multiple ancestries to identify variants associated with SBP, diastolic BP (DBP), mean arterial pressure (MAP), and pulse pressure (PP). We tested a model that included a joint model of SNV main effect on BP and SNV-alcohol consumption interaction, in each ancestry and across ancestries. Alcohol consumption was defined by two categories: (I) as current drinking (yes/no), and (II) in the subset of drinkers, as light/heavy drinking (1--7 drinks/week or ≥8 drinks/week). Individual cohort results were meta-analyzed using a modified version of METAL applicable to the statistics summary results accounting for interactions\[[@pone.0198166.ref024]\]. We also performed multi-trait correlated meta-analyses\[[@pone.0198166.ref025], [@pone.0198166.ref026]\] in participants of European ancestry using the joint model *P*-values from each meta-analysis of all four BP traits.

Results {#sec002}
=======

Genetic associations for BP identified via gene-alcohol interaction {#sec003}
-------------------------------------------------------------------

The overall description of the CHARGE Gene-Lifestyle Interactions Working Group was previously reported\[[@pone.0198166.ref022], [@pone.0198166.ref023]\]. We studied the joint model of SNV main effect and SNV-alcohol consumption interaction for BP in a two-stage study design, as depicted in [S1 Fig](#pone.0198166.s003){ref-type="supplementary-material"}. GWAS discovery (Stage 1), was conducted in each of 47 multi-ancestry cohorts including a total of 130,828 individuals of African ancestry (N = 21,417), Asian ancestry (N = 9,838), Brazilian (4,415), European ancestry (N = 91,102), and Hispanic ancestry (N = 4,056) ([S1](#pone.0198166.s021){ref-type="supplementary-material"}--[S4](#pone.0198166.s024){ref-type="supplementary-material"} Tables and [S1 Note](#pone.0198166.s001){ref-type="supplementary-material"}). A total of 3,514 SNVs (245 loci) attained *P* \< 1.0 x 10^−5^ in Stage 1 meta-analyses (for at least one combination of BP trait and alcohol consumption status in one ancestry or multi-ancestries). We considered a locus to be independent, if our lead variant (i.e., most significant) was in low linkage disequilibrium (LD, r^2^ ≤ 0.2) and at least 500 kb away from any variant associated with BP in previous GWAS (*P* ≤ 5.0 x 10^−8^). The meta-analysis distributions of--log~10~ *P*-values of observed versus--log~10~ *P*-values expected (QQ plots) are shown in [S2](#pone.0198166.s004){ref-type="supplementary-material"} and [S3](#pone.0198166.s005){ref-type="supplementary-material"} Figs.

The 3,514 SNVs were taken forward to replication, Stage 2, which included 440,824 individuals from 68 cohorts of African ancestry (N = 5,041), Asian ancestry (N = 141,026), European ancestry (N = 281,380), and Hispanic ancestry (N = 13,377, [S5](#pone.0198166.s025){ref-type="supplementary-material"}--[S8](#pone.0198166.s028){ref-type="supplementary-material"} Tables and [S1 Note](#pone.0198166.s001){ref-type="supplementary-material"}). We identified and replicated (Stage 2, at Bonferroni correction *P* \< 0.0002) five novel BP loci in European ancestry, four loci on 8p23.1 and one locus (*FTO*) on 16q12.2, which included 380 SNVs in 21 genes. These findings achieved genome-wide statistical significance (*P* \< 5.0 x 10^−8^) in Stage 1 and Stage 2 combined meta-analyses. Tables [1](#pone.0198166.t001){ref-type="table"} and [2](#pone.0198166.t002){ref-type="table"} show the most significant SNVs per BP trait, per alcohol consumption and gene for European ancestry participants. The loci containing novel BP associations at 8p23.1 were detected for all four BP traits in current drinkers and in light/heavy drinkers. The regional association plots on chromosomes 8p23 and 16q12 in European ancestry are shown in [S4](#pone.0198166.s006){ref-type="supplementary-material"} and [S5](#pone.0198166.s007){ref-type="supplementary-material"} Figs. For African ancestry, 18 potentially novel BP loci were found in discovery (*P* ≤ 5.0 x 10^−8^), but without replication ([Table 3](#pone.0198166.t003){ref-type="table"}). Further, we performed combined meta-analyses of Stage 1 and Stage 2 across all ancestries, which reproduced our European ancestry findings (*P* ≤ 5.0 x 10^−8^, [Table 4](#pone.0198166.t004){ref-type="table"} and [S9](#pone.0198166.s029){ref-type="supplementary-material"} Table). We also identified and replicated 49 previously reported BP loci (2,159 SNVs in 109 genes) for European ancestry participants ([S10 Table](#pone.0198166.s030){ref-type="supplementary-material"}). For African Ancestry, and multi-ancestry analyses, additional reported BP loci were significant (*P* \< 5.0 x 10^−8^) in Stage 1 and Stage 2 combined meta-analyses ([S11](#pone.0198166.s031){ref-type="supplementary-material"} and [S12](#pone.0198166.s032){ref-type="supplementary-material"} Tables). Manhattan plots for BP trait and alcohol consumption status are shown in [S6](#pone.0198166.s008){ref-type="supplementary-material"}--[S15](#pone.0198166.s017){ref-type="supplementary-material"} Figs, for Stage 1 and Stage 2 combined meta-analyses of European, African and Asian ancestries.

10.1371/journal.pone.0198166.t001

###### Novel SNVs/Genes associated with BP traits in European ancestry.
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                                                                                            Stage 1 (S1)   Stage 2 (S2)   S1 & S2                                          
  ------------ --- ---------- -------------- ----------- -------- ----- ------ ----- ------ -------------- -------------- --------------- ------- ------- ---------------- ----------------
  rs2979172    8   8452998    LOC107986913   SGK223               C/G   0.48   PP    LHD    0.24           0.25           7.59 x 10^−6^   0.32    -0.20   5.13 X 10^−6^    6.17 X 10^−10^
  rs2921064    8   8459127    LOC107986913   SGK223               T/C   0.45   PP    CURD   0.19           0.10           7.76 X 10^−6^   0.24    -0.02   3.63 X 10^−9^    2.69 x 10^−14^
  rs2979181    8   8465578    LOC107986913   SGK223               A/T   0.52   SBP   CURD   -0.25          -0.23          9.33 x 10^−8^   -0.35   0.01    1.15 x 10^−10^   7.41 x 10^−18^
  rs2979181    8   8465578    LOC107986913   SGK223               A/T   0.52   SBP   LHD    -0.47          -0.14          5.37 x 10^−7^   -0.42   0.16    4.79 x 10^−5^    3.98 x 10^−11^
  rs2980755    8   8506173    LOC105379224   SGK223               A/G   0.55   PP    LHD    -0.28          -0.20          4.17 x 10^−6^   -0.32   0.17    4.90 x 10^−6^    1.35 x 10^−10^
  rs2980755    8   8506173    LOC105379224   SGK223               A/G   0.55   SBP   LHD    -0.49          -0.20          2.63 x 10^−7^   -0.42   0.12    5.25 x 10^−5^    2.51 x 10^−11^
  rs13270194   8   8520592    LOC105379224   SGK223               T/C   0.51   SBP   CURD   -0.26          -0.24          2.46 x 10^−8^   -0.42   0.05    1.23 x 10^−12^   2.34 x 10^−20^
  rs6995407    8   8527137    LOC105379224   SGK223               C/G   0.51   PP    CURD   -0.16          -0.15          7.59 x 10^−7^   -0.25   0.02    2.34 x 10^−10^   2.34 x 10^−16^
  rs453301     8   9172877    LOC102724880   PPP1R3B              T/G   0.51   SBP   CURD   -0.17          -0.33          1.59 x 10^−6^   -0.27   -0.08   8.13 x 10^−10^   1.23 x 10^−15^
  rs11774915   8   9331252    LOC157273                  Intron   T/C   0.33   SBP   CURD   0.45           0.01           1.02 x 10^−7^   0.35    -0.05   7.94 x 10^−8^    8.91 x 10^−15^
  rs6601302    8   9381948    LOC105379231   LOC157273   Intron   T/G   0.24   SBP   CURD   0.35           0.17           7.94 x 10^−7^   0.20    0.06    7.59 x 10^−5^    2.57 x 10^−10^
  rs35231275   8   9762399    TNKS                       Intron   A/T   0.31   PP    CURD   -0.38          0.03           1.26 x 10^−6^   -0.05   -0.12   3.31 x 10^−4^    1.35 x 10^−8^
  rs1976671    8   9822124    TNKS                                A/G   0.62   SBP   CURD   -0.21          -0.31          4.68 x 10^−8^   -0.37   -0.02   2.24 x 10^−10^   7.24 x 10^−18^
  rs55868514   8   9822890    TNKS                                T/C   0.38   DBP   CURD   0.20           0.09           1.32 x 10^−6^   0.17    0.01    1.20 x 10^−7^    1.70 x 10^−13^
  rs483916     8   9936091    MIR124-1                            A/C   0.47   DBP   CURD   0.25           0.01           1.18 x 10^−6^   0.04    0.14    1.29 x 10^−6^    5.89 x 10^−12^
  rs483916     8   9936091    MIR124-1                            A/C   0.47   PP    CURD   0.20           0.09           7.94 x 10^−6^   0.16    0.03    4.68 x 10^−12^   6.61 x 10^−17^
  rs483916     8   9936091    MIR124-1                            A/C   0.47   SBP   CURD   0.38           0.17           1.05 x 10^−9^   0.21    0.16    3.24 x 10^−11^   3.31 x 10^−20^
  rs615632     8   9938811    MIR124-1                            T/C   0.53   SBP   LHD    -0.50          -0.30          7.41 x 10^−9^   -0.40   0.09    1.07 x 10^−4^    3.63 x 10^−12^
  rs9650622    8   9946782    LOC105379235   MIR124-1             T/G   0.53   DBP   CURD   -0.24          -0.01          4.07 x 10^−6^   -0.12   -0.07   1.10 x 10^−7^    4.27 x 10^−13^
  rs56243511   8   9948185    LOC105379235   MIR124-1             T/C   0.47   SBP   CURD   0.37           0.11           2.57 x 10^−8^   0.27    0.14    1.91 x 10^−13^   1.74 x 10^−21^
  rs656319     8   9956901    LOC105379235   MIR124-1             A/G   0.45   MAP   LHD    0.29           0.20           1.29 x 10^−6^   0.24    0.06    6.03 x 10^−5^    7.59 x 10^−11^
  rs656319     8   9956901    LOC105379235   MIR124-1             A/G   0.45   SBP   LHD    0.39           0.35           8.71 x 10^−7^   0.43    0.01    1.62 x 10^−6^    1.59 x 10^−12^
  rs11786677   8   10406750   MSRA                       Intron   A/G   0.58   SBP   CURD   -0.25          -0.22          2.57 x 10^−7^   -0.40   0.03    1.35 x 10^−42^   5.62 x 10^−49^
  rs2062331    8   10122482   MSRA                       Intron   A/G   0.54   DBP   CURD   -0.18          -0.15          2.00 x 10^−8^   -0.18   0.00    7.59 x 10^−8^    5.01 x 10^−15^
  rs11993089   8   10152442   MSRA                       Intron   T/G   0.42   PP    CURD   0.24           0.05           5.25 x 10^−6^   0.32    -0.13   4.68 x 10^−18^   6.17 x 10^−23^
  rs7832708    8   10332530   MSRA                       Intron   T/C   0.49   SBP   LHD    0.55           0.07           2.19 x 10^−8^   0.42    -0.09   2.19 x 10^−5^    5.89 x 10^−13^
  rs4841409    8   10658864   RP1L1                               A/G   0.44   MAP   CURD   0.18           0.14           7.59 x 10^−7^   0.27    -0.12   9.77 x 10^−6^    5.13 x 10^−11^
  rs4841409    8   10658864   RP1L1                               A/G   0.44   MAP   LHD    0.37           -0.14          6.03 x 10^−6^   0.36    -0.19   2.14 x 10^−6^    6.46 x 10^−12^
  rs4841409    8   10658864   RP1L1                               A/G   0.44   SBP   CURD   0.23           0.25           1.91 x 10^−7^   0.32    0.12    9.55 x 10^−16^   4.90 x 10^−23^
  rs10096777   8   10660990   RP1L1                               A/G   0.56   SBP   LHD    -0.52          0.10           1.55 x 10^−6^   -0.60   0.39    2.88 x 10^−8^    3.80 x 10^−14^
  rs7814795    8   10661775   MIR4286                             T/C   0.55   MAP   CURD   -0.18          -0.14          7.59 x 10^−7^   -0.22   0.08    1.45 x 10^−4^    9.77 x 10^−10^
  rs7814795    8   10661775   MIR4286                             T/C   0.55   SBP   CURD   -0.22          -0.26          1.78 x 10^−7^   -0.2    -0.15   2.29 x 10^−14^   1.48 x 10^−21^
  rs7814795    8   10661775   MIR4286                             T/C   0.55   SBP   LHD    -0.50          0.06           2.04 x 10^−6^   -0.59   0.38    3.80 x 10^−8^    7.76 x 10^−14^

The most significantly associated SNVs are shown per gene for each Blood Pressure (BP) trait and alcohol status. Abbreviations: SNV, single nucleotide variant; Chr, chromosome; Position, Gene, and Role in dbSNP build 150 (hg38); Role: Intronic, Non-coding transcript (NCT) or intergenic (blank space) SNV; Near gene reflects genes at up to +/-500 kb and related to BP / alcohol; A1/2, Coded and non-coded alleles; Frq1, Frequency of coded allele; Trait, SBP: Systolic BP, DBP: Diastolic BP, MAP: Mean Arterial Pressure, PP: Pulse Pressure; Drink: Alcohol consumption, CURD, Current drinker (yes/no), LHD, Light(1--7 drinks/week) or heavy (≥8 drinks/week) drinker; Stage 1, Discovery cohorts; Stage 2, Replication cohorts; S1 & S2,Combined Discovery and Replication; b_M, beta coefficient of SNV; b_I: SNV\*E is SNV-alcohol interaction effect; P-Value: modified-interaction METAL P-Value; P-Meta, modified-interaction METAL P-Value of Meta-analysis in combined Stage 1 and Stage 2.

10.1371/journal.pone.0198166.t002

###### Novel SNVs/Genes associated with BP traits in European ancestry.
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                                                                                             Stage 1 (S1)   Stage 2 (S2)   S1 & S2                                          
  ------------ ---- ---------- -------------- ----------- -------- ----- ------ ----- ------ -------------- -------------- --------------- ------- ------- ---------------- ----------------
  rs28680211   8    10661935   MIR4286                             A/T   0.55   MAP   LHD    -0.36          0.13           7.76 x 10^−6^   -0.35   0.19    3.98 x 10^−6^    1.59 x 10^−11^
  rs13276026   8    10752445   LOC102723313   SOX7        Intron   A/G   0.56   SBP   CURD   -0.23          -0.23          5.62 x 10^−7^   -0.26   -0.19   2.29 x 10^−15^   3.98 x 10^−22^
  rs7814757    8    10817678   PINX1                      Intron   T/C   0.40   SBP   CURD   0.24           0.22           7.94 x 10^−7^   0.21    0.26    8.71 x 10^−16^   2.63 x 10^−22^
  rs4841465    8    10962344   XKR6                       Intron   T/C   0.52   SBP   CURD   -0.21          -0.27          6.17 x 10^−7^   -0.21   -0.21   6.03 x 10^−14^   1.41 x 10^−20^
  rs4841465    8    10962344   XKR6                       Intron   T/C   0.52   SBP   LHD    -0.51          -0.10          3.89 x 10^−7^   -0.43   0.04    4.07 x 10^−6^    1.23 x 10^−12^
  rs9969423    8    11398066   FAM167A-AS1    C8orf12     Intron   A/C   0.50   SBP   CURD   0.21           0.2            3.98 X 10^−6^   0.29    0.01    1.20 x 10^−7^    5.37 x 10^−13^
  rs9969423    8    11398066   FAM167A-AS1    C8orf12     Intron   A/C   0.50   SBP   LHD    0.52           -0.09          4.90 X 10^−6^   0.38    -0.07   1.95 X 10^−4^    8.13 X 10^−10^
  rs12156009   8    11427710   FAM167A        C8orf12     Intron   A/C   0.51   SBP   CURD   0.29           0.21           1.66 X 10^−7^   0.17    0.10    1.02 X 10^−5^    5.37 X 10^−12^
  rs13255193   8    11451683   FAM167A        FAM167A     Intron   T/C   0.46   SBP   LHD    0.53           -0.11          6.76 X 10^−7^   0.36    -0.11   7.76 X 10^−4^    6.17 X 10^−10^
  rs6983727    8    11558303   BLK                        Intron   T/C   0.48   PP    CURD   -0.15          -0.15          4.68 X 10^−6^   -0.17   -0.08   1.66 X 10^−10^   5.89 X 10^−16^
  rs6983727    8    11558303   BLK                        Intron   T/C   0.48   PP    LHD    -0.24          -0.25          5.89 X 10^−6^   -0.26   0.07    6.03 X 10^−5^    1.74 X 10^−9^
  rs6983727    8    11558303   BLK                        Intron   T/C   0.48   SBP   LHD    -0.47          -0.17          4.27 X 10^−7^   -0.34   0.00    1.55 X 10^−4^    1 X 10^−10^
  rs34190028   8    11559641   BLK                        Intron   T/G   0.48   SBP   CURD   -0.16          -0.31          5.13 X 10^−7^   -0.36   -0.04   3.47 X 10^−13^   1.26 X 10^−19^
  rs899366     8    11572976   LINC00208                           A/G   0.33   MAP   CURD   0.15           0.18           3.39 X 10^−6^   0.28    0.00    3.47 X 10^−79^   1.51 X 10^−82^
  rs7464263    8    11576667   LINC00208                  NCT      A/T   0.48   SBP   LHD    0.48           0.24           6.03 X 10^−8^   0.41    -0.08   3.72 X 10^−5^    4.37 X 10^−12^
  rs1478894    8    11591245   LINC00208                           T/C   0.36   SBP   CURD   0.33           0.21           1.00 X 10^−8^   0.24    0.16    3.31 X 10^−11^   2.51 X 10^−19^
  rs4841569    8    11594668   LINC00208                           A/G   0.42   PP    CURD   -0.10          -0.28          1.95 X 10^−7^   -0.07   -0.18   1.23 X 10^−10^   4.17 X 10^−17^
  rs4841569    8    11594668   LINC00208                           A/G   0.42   PP    LHD    -0.27          -0.44          2.88 X 10^−8^   -0.28   0.08    2.40 X 10^−5^    4.79 X 10^−11^
  rs17807624   8    11605506   LINC00208                           T/C   0.35   DBP   CURD   0.11           0.20           5.37 X 10^−6^   0.14    0.05    8.13 X 10^−8^    6.03 X 10^−13^
  rs17807624   8    11605506   LINC00208                           T/C   0.35   MAP   LHD    0.45           -0.22          5.13 X 10^−7^   0.32    -0.16   6.03 X 10^−5^    2.57 X 10^−11^
  rs13280442   8    11610048   LOC105379242   LINC00208            C/G   0.55   MAP   CURD   0.23           0.11           1.29 X 10^−6^   0.28    -0.17   4.90 X 10^−4^    1.62 X 10^−8^
  rs13280442   8    11610048   LOC105379242   LINC00208            C/G   0.55   MAP   LHD    0.40           -0.11          3.39 X 10^−6^   0.28    -0.01   5.25 X 10^−5^    1.38 X 10^−10^
  rs13280442   8    11610048   LOC105379242   LINC00208            C/G   0.55   SBP   CURD   0.30           0.24           8.32 X 10^−8^   0.48    -0.03   1.91 X 10^−16^   9.12 X 10^−24^
  rs13280442   8    11610048   LOC105379242   LINC00208            C/G   0.55   SBP   LHD    0.57           0.10           1.38 X 10^−7^   0.50    -0.10   4.68 X 10^−7^    5.01 X 10^−14^
  rs13250871   8    11610254   LOC105379242   LINC00208            A/G   0.4    PP    CURD   -0.10          -0.27          8.51 X 10^−7^   -0.21   -0.10   2.63 X 10^−17^   1.91 X 10^−23^
  rs13250871   8    11610254   LOC105379242   LINC00208            A/G   0.39   PP    LHD    -0.24          -0.49          7.59 X 10^−8^   -0.29   0.10    2.69 X 10^−5^    2.14 X 10^−10^
  rs36038176   8    11752486   GATA4                      Intron   T/C   0.28   SBP   CURD   -0.21          -0.29          1.07 X 10^−6^   -0.39   0.15    3.89 X 10^−5^    3.24 X 10^−10^
  rs55872725   16   53775211   FTO                        Intron   T/C   0.41   SBP   CURD   0.69           -0.31          3.39 X 10^−9^   0.36    -0.16   2.14 X 10^−5^    2.40 X 10^−13^
  rs7185735    16   53788739   FTO                        Intron   A/G   0.59   PP    CURD   -0.36          0.07           6.31 X 10^−8^   -0.25   0.14    3.31 X 10^−4^    2.09 X 10^−10^

The most significantly associated SNVs are shown per gene for each Blood Pressure (BP) trait and alcohol status. Abbreviations: SNV, single nucleotide variant; Chr, chromosome; Position, Gene, and Role in dbSNP build 150 (hg38); Role: Intronic, Non-coding transcript (NCT) or intergenic (blank space) SNV; Near gene reflects genes at up to +/-500 kb and related to BP / alcohol; A1/2, Coded and non-coded alleles; Frq1, Frequency of coded allele; Trait, SBP: Systolic BP, DBP: Diastolic BP, MAP: Mean Arterial Pressure, PP: Pulse Pressure; Drink: Alcohol consumption, CURD, Current drinker (yes/no), LHD, Light(1--7 drinks/week) or heavy (≥8 drinks/week) drinker; Stage 1, Discovery cohorts; Stage 2, Replication cohorts; S1 & S2,Combined Discovery and Replication; b_M, beta coefficient of SNV; b_I: SNV\*E is SNV-alcohol interaction effect; P-Value: modified-interaction METAL P-Value; P-Meta, modified-interaction METAL P-Value of Meta-analysis in combined Stage 1 and Stage 2.

10.1371/journal.pone.0198166.t003

###### Potential novel SNVs/Genes associated with BP traits in African ancestry.
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  rs80158983    6         65489746       EYS            EYS                  intron     T/C        0.02       SBP         CURD        3.53               -10.05                1.29 x 10^−8^   0.95    -3.08   8.32 x 10^−1^   6.92 x 10^−9^
  rs76987554    6         133759717      TARID          MGC34034, SGK1       intron     T/C        0.09       SBP         CURD        -2.45              0.80                  2.19 x 10^−8^   -1.48   -0.42   2.09 x 10^−1^   1.86 x 10^−9^
  rs79505281    8         35841899       UNC5D                                          A/C        0.02       PP          CURD        -5.66              1.26                  6.03 x 10^−7^   1.50    -6.67   2.82 x 10^−3^   3.24 x 10^−9^
  rs115888294   8         94105161       CDH17                                          T/C        0.93       PP          CURD        -1.18              -0.55                 1.59 x 10^−7^   -0.71   -0.84   2.19 x 10^−1^   1.29 x 10^−8^
  rs73655199    9         98145201       CORO2A         GABBR2               intron     A/G        0.01       PP          CURD        -5.09              -0.13                 3.16 x 10^−9^   -0.45   -2.71   2.95 x 10^−1^   1.41 x 10^−9^
  rs4253197     10        49473111       ERCC6          CHAT                 intron     A/G        0.89       PP          CURD        0.66               0.67                  6.61 x 10^−7^   -0.80   2.57    3.63 x 10^−2^   4.90 x 10^−8^
  rs11200509    10        122256927      TACC2                                          C/G        0.17       PP          LHD         -0.27              -4.05                 6.76 x 10^−9^   1.72    -2.92   1.45 x 10^−1^   1.00 x 10^−8^
  rs10741534    11        11233360       GALNT18                                        T/C        0.09       SBP         CURD        2.34               -3.76                 8.32 x 10^−8^   0.94    -2.76   2.29 x 10^−1^   1.18 x 10^−8^
  rs139077481   11        107579224      ELMOD1                                         T/C        0.99       PP          CURD        -3.18              10.41                 1.32 x 10^−7^   -0.81   4.67    3.47 x 10^−1^   3.39 x 10^−8^
  rs140520944   18        29508647       LOC105372045   MIR302F                         T/G        0.02       PP          CURD        -0.49              -4.83                 1 x 10^−12^     1.94    -3.30   6.03 x 10^−1^   4.07 x 10^−13^
  rs142673685   19        31669942       LOC105372361   THEG5                           T/C        0.01       PP          CURD        -3.04              -2.20                 5.01 x 10^−8^   -2.92   2.29    4.47 x 10^−1^   3.63 x 10^−8^
                                                                                                                                      **Stage 1 (S1)**   **No Stage 2 (S2)**                                                   
  **SNV**       **Chr**   **Position**   **Gene**       **Near Gene**        **Role**   **A1/2**   **Frq1**   **Trait**   **Drink**   **b_M**            **b_I**               ***P*-Value**                                   
  rs9862344     3         178283140      LOC105374235   KCNMB2, KCNMB2-IT1              T/C        0.02       SBP         CURD        3.53               -10.05                1.29 x 10^−8^                                   
  rs73884351    3         178287933      LOC105374235   KCNMB2, KCNMB2-IT1              T/C        0.09       SBP         CURD        -2.45              0.80                  2.19 x 10^−8^                                   
  rs145429126   4         47000363       GABRB1         GABRA4               intron     A/C        0.02       PP          CURD        -5.66              1.26                  6.03 x 10^−7^                                   
  rs61494734    9         29196976       LINGO2                              intron     T/C        0.93       PP          CURD        -1.18              -0.55                 1.59 x 10^−7^                                   
  rs201383951   10        119468517      GRK5           BAG3                            A/G        0.01       PP          CURD        -5.09              -0.13                 3.16 x 10^−9^                                   
  rs186331780   12        61317029       LOC105369793   FAM19A2                         A/G        0.89       PP          CURD        0.66               0.67                  6.61 x 10^−7^                                   
  rs187888844   13        67705907       LOC105370250   PCDH9                           C/G        0.17       PP          LHD         -0.27              -4.05                 6.76 x 10^−9^                                   
  rs116464496   13        105934773      LINC00343                                      T/C        0.09       SBP         CURD        2.34               -3.76                 8.32 x 10^−8^                                   

The most significantly associated SNVs are shown per gene for each Blood Pressure (BP) trait and alcohol status. Abbreviations: SNV, single nucleotide variant; Chr, chromosome; Position, Gene, and Role in dbSNP build 150 (hg38); Role: Intronic or intergenic (blank space) SNV; Near gene reflects genes at up to +/-500 kb and related to BP / alcohol; A1/2, Coded and non-coded alleles; Frq1, Frequency of coded allele; Trait, SBP: Systolic BP, DBP: Diastolic BP, MAP: Mean Arterial Pressure, PP: Pulse Pressure; Drink: Alcohol consumption, CURD, Current drinker (yes/no), LHD, Light(1--7 drinks/week) or heavy (≥8 drinks/week) drinker; Stage 1, Discovery cohorts; Stage 2, Replication cohorts; S1 & S2,Combined Discovery and Replication; b_M, beta coefficient of SNV; b_I: SNV\*E is SNV-alcohol interaction effect; P-Value: modified-interaction METAL P-Value; P-Meta, modified-interaction METAL P-Value of Meta-analysis in combined Stage 1 and Stage 2

10.1371/journal.pone.0198166.t004

###### Novel SNVs/Genes associated with BP traits in Multi-ancestry meta-analysis in combined Stage 1 and Stage 2.
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               Stage 1 and Stage 2                                                                                                                     
  ------------ --------------------- ---------- -------------- --------- -------- ----- ------ --------- ----- ------ ------- ------- ---------------- ---------
  rs10092965   8                     8515975    LOC105379224   SGK223             A/G   0.53   EA, HA    DBP   CURD   -0.19   0.01    1.74 x 10^−12^   373,915
  rs7823056    8                     8525195    LOC105379224   SGK223             A/G   0.5    AA, EA    PP    LHD    -0.31   0.10    3.31 x 10^−11^   161,080
  rs7823056    8                     8525195    LOC105379224   SGK223             A/G   0.41   AA, EA    SBP   LHD    -0.44   0.11    1.38 x 10^−11^   214,814
  rs453301     8                     9172877    LOC102724880   PPP1R3B            T/G   0.5    EA, HA    DBP   CURD   -0.13   -0.07   4.90 x 10^−12^   365,537
  rs10503387   8                     9293015    LOC157273                         T/C   0.37   AA, EA    SBP   CURD   0.32    0.03    1.07 x 10^−14^   381,431
  rs11781008   8                     9295729    LOC157273                         T/G   0.37   EA, HA    DBP   CURD   0.13    0.07    1.05 x 10^−11^   373,915
  rs4383974    8                     9761838    TNKS                     intron   C/G   0.7    AA, EA    SBP   CURD   -0.28   -0.08   2.04 x 10^−13^   381,431
  rs9286060    8                     9795635    TNKS                              A/C   0.38   AA, EA    DBP   CURD   0.21    -0.02   2.29 x 10^−13^   371,053
  rs34919878   8                     10241994   MSRA                     intron   A/G   0.41   EA, HA    DBP   CURD   -0.18   -0.05   5.75 x 10^−17^   365,537
  rs4841294    8                     10247558   MSRA                     intron   A/C   0.43   AA, EA    SBP   LHD    -0.40   0.01    2.69 x 10^−10^   166,956
  rs17693945   8                     10248500   MSRA                     intron   T/C   0.41   AA, EA    MAP   LHD    -0.30   0.08    1.51 x 10^−9^    166,054
  rs13276026   8                     10752445   LOC102723313   PINX1     intron   A/G   0.55   EA, HA    DBP   CURD   -0.11   -0.10   4.47 x 10^−14^   373,915
  rs13276026   8                     10752445   LOC102723313   PINX1     intron   A/G   0.55   EA, HA    MAP   CURD   -0.15   -0.03   4.68 x 10^−9^    373,911
  rs13276026   8                     10752445   LOC102723313   PINX1     intron   A/G   0.55   EA, HA    SBP   CURD   -0.22   -0.24   3.89 x 10^−23^   373,919
  rs4551304    8                     10807559   PINX1                    intron   A/G   0.4    EA, HA    DBP   CURD   0.10    0.12    1.70 x 10^−14^   373,915
  rs4551304    8                     10807559   PINX1                    intron   A/G   0.4    EA, HA    MAP   CURD   0.15    0.03    2.24 x 10^−8^    373,911
  rs9969436    8                     10985149   XKR6                     intron   T/G   0.47   AA, EA    MAP   LHD    0.28    -0.01   3.09 x 10^−9^    165,894
  rs2409784    8                     11539347   BLK                      intron   A/C   0.51   EA, HA    DBP   CURD   -0.11   -0.09   5.62 x 10^−12^   374,975
  rs2244894    8                     11591150   LINC00208                         C/G   0.44   ASA, EA   PP    CURD   -0.07   -0.19   3.24 x 10^−15^   493,402
  rs13249843   8                     11601509   LINC00208                         T/G   0.33   EA, HA    DBP   CURD   0.18    0.04    2.51 x 10^−15^   398,330
  rs3735814    8                     11749887   GATA4                    intron   A/G   0.52   EA, HA    SBP   CURD   0.09    0.22    2.14 x 10^−10^   373,919
  rs9928094    16                    53765993   FTO                      intron   A/G   0.63   ASA, EA   PP    CURD   -0.33   0.19    2.63 x 10^−15^   499,179
  rs62033406   16                    53790314   FTO                      intron   A/G   0.55   ASA, EA   MAP   CURD   -0.22   0.12    3.31 x 10^−8^    511,074

The most significantly associated SNVs are shown per gene for each Blood Pressure (BP) trait and alcohol status. Abbreviations: SNV, single nucleotide variant; Chr, chromosome; Position, Gene, and Role, in dbSNP build 150 (hg38) annotation; Role: Intronic or intergenic (blank space) SNV; Near gene reflects genes at up to +/-500 kb and related to BP / alcohol; A1/2, Coded and non-coded alleles; Frq1, Frequency of coded allele; Trait, SBP: Systolic BP, DBP: Diastolic BP, MAP: Mean Arterial Pressure, PP: Pulse Pressure; Drink: Alcohol consumption, CURD, Current drinker (yes/no), LHD, Light(1--7 drinks/week) or heavy (≥8 drinks/week) drinker; Stage 1 and Stage 2, Combined Discovery and Replication; b_M, beta coefficient of SNV; b_I: SNV\*E is SNV-alcohol interaction effect; P-Meta, modified-interaction METAL P-Value of Meta-analysis in combined Stage 1 and Stage 2; N, Number of individuals.

Finally, we leveraged the added power of correlated meta-analysis\[[@pone.0198166.ref025], [@pone.0198166.ref026]\] for BP traits to detect additional variants. We performed correlated meta-analysis on *P*-values from METAL-meta-analysis\[[@pone.0198166.ref024]\] of DBP, SBP, MAP and PP traits separately for current drinkers and light/heavy drinkers in Stage 1 European ancestry cohorts. A variant was considered pleiotropic if the *P*- METAL-meta reached *P* ≤ 0.0001 in two or more BP traits and the correlated meta-analysis *P*-value was *P* ≤ 5.0 x 10^−8^\[[@pone.0198166.ref027]\]. We identified eight novel BP loci (11 genes, [Table 5](#pone.0198166.t005){ref-type="table"}), the above five novel loci (14 genes, Tables [1](#pone.0198166.t001){ref-type="table"} and [2](#pone.0198166.t002){ref-type="table"}), and the 22 previously reported BP loci (49 genes).

10.1371/journal.pone.0198166.t005

###### Novel SNVs/Genes associated with BP traits from correlated meta-analysis in European ancestry in Stage 1.
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------- --------- -------------- -------------- --------------- ---------- ---------- ------------------------- --------------- ---------------- ---------------- --------------- --------
  **Associations NOT Present in Tables [1](#pone.0198166.t001){ref-type="table"} and [2](#pone.0198166.t002){ref-type="table"}, in Current Drinkers**                                                                                                                                                                                   
  **SNV**                                                                                                                                                     **Chr**   **Position**   **Gene**       **Near Gene**   **Role**   **Frq1**   ***P*-Correlated Meta**   ***P*-DBP**     ***P*-SBP**      ***P*-MAP**      ***P*-PP**      **N**
  rs200124401                                                                                                                                                 1         83336112       LOC107985037   TTLL7           intron     0.70       4.29 x 10^−8^             1.82 x 10^−5^   1.86 x 10^−6^    1.20 x 10^−6^    4.68 x 10^−4^   89,035
  rs3813963                                                                                                                                                   1         206648224      DYRK3          DYRK3, IL10     Synon      0.99       2.95 x 10^−8^             1.66 x 10^−4^   8.32 x 10^−8^    8.13 x 10^−7^    3.72 x 10^−4^   39,497
  rs80169249                                                                                                                                                  1         206683281      LOC105372875   MAPKAPK2                   0.99       3.52 x 10^−8^             2.45 x 10^−4^   7.41 x 10^−8^    1.00 x 10^−6^    3.39 x 10^−4^   39,497
  rs185597356                                                                                                                                                 4         161336738      FSTL5          FSTL5                      0.99       1.77 x 10^−8^             7.24 x 10^−7^   8.71 x 10^−7^    4.37 x 10^−8^    1.00 x 10^−2^   55,056
  rs77779142                                                                                                                                                  11        65832185       SNX32          SNX32                      0.84       3.89 x 10^−8^             8.32 x 10^−5^   1.12 x 10^−6^    2.88 x 10^−6^    7.08 x 10^−5^   90,689
  rs11227333                                                                                                                                                  11        65874946       EFEMP2         EFEMP2                     0.80       2.34 x 10^−8^             3.24 x 10^−5^   5.89 x 10^−7^    1.15 x 10^−6^    2.00 x 10^−4^   86,262
  rs201407003                                                                                                                                                 11        65894964       FOSL1          FOSL1, MALAT1   intron     0.85       1.76 x 10^−8^             2.09 x 10^−5^   6.31 x 10^−7^    7.94 x 10^−7^    2.04 x 10^−4^   86,262
  **Associations Present in Tables [1](#pone.0198166.t001){ref-type="table"} and [2](#pone.0198166.t002){ref-type="table"}, in Current Drinkers**                                                                                                                                                                                       
  **SNV**                                                                                                                                                     **Chr**   **Position**   **Gene**       **Near Gene**   **Role**   **Frq1**   ***P*-Correlated Meta**   ***P*-DBP**     ***P*-SBP**      ***P*-MAP**      ***P*-PP**      **N**
  rs2980755                                                                                                                                                   8         8506173        LOC107986913   SGK223                     0.55       4.59 x 10^−9^             5.13 x 10^−4^   4.27 x 10^−8^    1.74 x 10^−6^    1.15 x 10^−6^   90,691
  rs13270194                                                                                                                                                  8         8520592        LOC105379224   CLDN23                     0.51       1.59 x 10^−9^             2.14 x 10^−4^   2.45 x 10^−8^    8.13 x 10^−7^    8.51 x 10^−7^   90,691
  rs1976671                                                                                                                                                   8         9822124        TNKS           TNKS                       0.62       2.01 x 10^−9^             1.58 x 10^−6^   4.68 x 10^−8^    3.02 x 10^−8^    1.26 x 10^−3^   90,691
  rs483916                                                                                                                                                    8         9936091        MIR124-1       MIR124-1                   0.47       1.55 x 10^−11^            1.17 x 10^−6^   1.05 x 10^−9^    3.55 x 10^−9^    7.94 x 10^−6^   90,691
  rs2062331                                                                                                                                                   8         10122482       MSRA           MSRA            intron     0.54       5.49 x 10^−13^            2.00 x 10^−8^   1.70 x 10^−10^   1.20 x 10^−10^   1.32 x 10^−5^   90,691
  rs10096777                                                                                                                                                  8         10660990       RP1L1          RP1L1                      0.44       7.58 x 10^−9^             9.77 x 10^−5^   1.91 x 10^−7^    9.55 x 10^−7^    1.51 x 10^−5^   90,691
  rs7814795                                                                                                                                                   8         10661775       MIR4286        MIR4286                    0.45       6.86 x 10^−9^             7.76 x 10^−5^   1.78 x 10^−7^    7.59 x 10^−7^    2.00 x 10^−5^   90,691
  rs13276026                                                                                                                                                  8         10752445       LOC102723313   SOX7            intron     0.44       4.79 x 10^−8^             1.38 x 10^−4^   5.62 x 10^−7^    1.58 x 10^−6^    1.91 x 10^−4^   90,691
  rs12156009                                                                                                                                                  8         11427710       FAM167A        FAM167A         intron     0.51       9.49 x 10^−9^             1.82 x 10^−4^   1.66 x 10^−7^    1.32 x 10^−6^    1.07 x 10^−5^   90,691
  rs1478894                                                                                                                                                   8         11591245       LINC00208      LINC00208                  0.64       3.69 x 10^−10^            1.66 x 10^−5^   1.00 x 10^−8^    8.51 x 10^−8^    8.32 x 10^−6^   90,691
  rs13280442                                                                                                                                                  8         11610048       LOC105379242   GATA4                      0.45       5.23 x 10^−9^             1.86 x 10^−4^   8.32 x 10^−8^    1.29 x 10^−6^    4.47 x 10^−6^   90,691
  rs9937521                                                                                                                                                   16        53765384       FTO            FTO             intron     0.61       2.89 x 10^−10^            8.13 x 10^−5^   4.68 x 10^−9^    6.46 x 10^−7^    2.04 x 10^−7^   90,691
  **Associations NOT Present in Tables [1](#pone.0198166.t001){ref-type="table"} and [2](#pone.0198166.t002){ref-type="table"}, in Light / Heavy Drinkers**                                                                                                                                                                             
  **SNV**                                                                                                                                                     **Chr**   **Position**   **Gene**       **Near Gene**   **Role**   **Frq1**   ***P*-Correlated Meta**   ***P*-DBP**     ***P*-SBP**      ***P*-MAP**      ***P*-PP**      **N**
  rs117519896                                                                                                                                                 15        43645473       CATSPER2       CATSPER2        intron     0.98       8.25 x 10^−9^             7.76 x 10^−5^   2.88 x 10^−7^    9.77 x 10^−7^    2.75 x 10^−5^   13,141
  rs2957398                                                                                                                                                   17        53625691       LOC107984982   LOC107984982               0.29       1.11 x 10^−8^             8.91 x 10^−5^   1.23 x 10^−7^    2.69 x 10^−6^    3.80 x 10^−5^   54,785
  rs146091319                                                                                                                                                 18        71962177       LOC102725148   LOC102725148               0.99       1.50 x 10^−8^             1.26 x 10^−3^   1.74 x 10^−8^    3.39 x 10^−6^    1.26 x 10^−5^   26,187
  rs111700101                                                                                                                                                 19        11433340       CCDC151        CCDC151         intron     0.94       2.78 x 10^−8^             3.80 x 10^−6^   8.13 x 10^−7^    3.80 x 10^−7^    3.55 x 10^−3^   37,996
  **Associations Present in Tables [1](#pone.0198166.t001){ref-type="table"} and [2](#pone.0198166.t002){ref-type="table"}, in Light / Heavy Drinkers**                                                                                                                                                                                 
  **SNV**                                                                                                                                                     **Chr**   **Position**   **Gene**       **Near Gene**   **Role**   **Frq1**   ***P*-Correlated Meta**   ***P*-DBP**     ***P*-SBP**      ***P*-MAP**      ***P*-PP**      **N**
  rs34062996                                                                                                                                                  8         9802688        TNKS           TNKS                       0.39       2.26 x 10^−9^             6.17 x 10^−5^   2.40 x 10^−8^    3.24 x 10^−7^    3.47 x 10^−5^   54,785
  rs615632                                                                                                                                                    8         9938811        MIR124-1       MIR124-1                   0.47       4.18 x 10^−10^            1.78 x 10^−5^   7.41 x 10^−9^    8.13 x 10^−8^    2.34 x 10^−5^   54,785
  rs7843924                                                                                                                                                   8         10119030       MSRA           MSRA            intron     0.54       2.46 x 10^−13^            1.38 x 10^−8^   1.58 x 10^−10^   1.58 x 10^−10^   6.46 x 10^−6^   54,785
  rs11250099                                                                                                                                                  8         10961147       XKR6           XKR6            intron     0.48       4.13 x 10^−8^             1.82 x 10^−4^   3.98 x 10^−7^    2.19 x 10^−6^    1.62 x 10^−4^   54,785
  rs13255193                                                                                                                                                  8         11451683       FAM167A        FAM167A         intron     0.46       2.41 x 10^−8^             7.76 x 10^−5^   6.76 x 10^−7^    1.66 x 10^−6^    9.77 x 10^−5^   54,785
  rs4841559                                                                                                                                                   8         11559376       BLK            BLK             intron     0.51       4.12 x 10^−8^             4.79 x 10^−4^   4.47 x 10^−7^    9.55 x 10^−6^    1.35 x 10^−5^   54,785
  rs4840573                                                                                                                                                   8         11605721       LINC00208      LINC00208                  0.60       3.94 x 10^−9^             1.15 x 10^−3^   7.76 x 10^−8^    7.59 x 10^−6^    4.57 x 10^−8^   53,371
  rs13280442                                                                                                                                                  8         11610048       LOC105379242   GATA4                      0.45       6.26 x 10^−9^             2.40 x 10^−4^   1.38 x 10^−7^    3.39 x 10^−6^    2.24 x 10^−6^   54,785
  ----------------------------------------------------------------------------------------------------------------------------------------------------------- --------- -------------- -------------- --------------- ---------- ---------- ------------------------- --------------- ---------------- ---------------- --------------- --------

The most significantly associated SNVs are shown per gene for correlated BP traits and alcohol status: Current drinker (yes/no), and Light (1--7 drinks/week) or heavy (≥8 drinks/ week) drinker. The "NOT Present in Tables [1](#pone.0198166.t001){ref-type="table"} and [2](#pone.0198166.t002){ref-type="table"}" represents the associations detected using correlated meta-approach, otherwise the associations were already presented in Tables [1](#pone.0198166.t001){ref-type="table"} and [2](#pone.0198166.t002){ref-type="table"} using modified-interaction METAL approach. Abbreviations: SNV, single nucleotide variant; Chr, chromosome; Position, Gene, and Role in dbSNP build 150 (hg38); Role: Intronic, synonymous codon (Synon), or intergenic (blank space) SNV; Near gene reflects genes at up to +/-500 kb and related to BP / alcohol; Frq1, Frequency of coded allele; P-Correlated Meta, P-Value of BP-correlated meta-analysis; P-DBP, modified-interaction METAL P-Value for Diastolic BP; P-SBP, modified-interaction METAL P-Value for Systolic BP; P-MAP, modified-interaction METAL P-Value for Mean Arterial Pressure; P-PP, modified-interaction METAL P-Value for Pulse Pressure; N, Number of individuals.

Gene transcription regulation {#sec004}
-----------------------------

HaploReg\[[@pone.0198166.ref028], [@pone.0198166.ref029]\], RegulomeDB\[[@pone.0198166.ref030], [@pone.0198166.ref031]\], GTEx\[[@pone.0198166.ref032]\], GWAS3D\[[@pone.0198166.ref033]\], and GRASP\[[@pone.0198166.ref034]\] provided evidence that several SNVs on 8p23.1 have regulatory features ([S13](#pone.0198166.s033){ref-type="supplementary-material"} and [S14](#pone.0198166.s034){ref-type="supplementary-material"} Tables). From the analyses with GTEx, a total of 227 (56 novel and 171 BP-known [S14](#pone.0198166.s034){ref-type="supplementary-material"} Tables) SNVs had tissue specific eQTL results. Seven out of 56 novel SNVs were associated with eQTLs that have expression in brain, thyroid, and/or blood. From 171 BP-known SNVs, 44 were significantly associated with eQTLs with expression in adipose, artery, esophagus, lung, pancreas, thyroid and/or fibroblasts. In addition, GWAS3D analyses suggested trans-regulation features for our BP candidate SNVs. It identified 215 SNVs with long-range interactions.

BP genes show enrichment for alcohol and cardiovascular disease {#sec005}
---------------------------------------------------------------

We used GeneGO\[[@pone.0198166.ref035]\] and Literature Lab\[[@pone.0198166.ref036]\] to perform enrichment analyses for the full set of novel and reported (179 BP candidate) genes identified from our analyses. Literature Lab, based on 106,967 abstracts for "*Drinking"* Physiology from MeSH (Medical Subject Headings), identified enrichment (*P* \< 0.00001) related to *ALDH2* (known to be associated with alcohol dependence)\[[@pone.0198166.ref015]\] and several other genes, including our novel finding for *ERCC6*, *CATSPER2*, *GABRB1* and *GATA4*. The main contributor for "*Angiotensin II"* (*P* \< 0.00001) was *AGT* and *ACE* for "*Hypertension"* (*P* = 0.0002). *AGT* and *ACE* are part of *Renin-Angiotensin System* pathway (*KEGG*, *map04614*), involved in BP homeostasis, fluid-electrolyte balance, and essential hypertension\[[@pone.0198166.ref037], [@pone.0198166.ref038]\].

Our results were significantly enriched for cardiovascular disease-related biological functions. For example, "Cardiovascular Diseases" (*P* = 0.0034) enriched with genes *AGT*, *NPPA*, *ACE*, *NOS3*, *ADRB1*, *MTHFR*, *FBN1* and *GATA4*. "Heart Failure" (*P* = 0.0003) and "Cardiomegaly" (*P* = 0.0003); from Pathological Conditions: "Hypertrophy" (*P* = 0.0001); from Anatomy MeSH: "Heart" (*P* = 0.0001), "Cardiovascular System" (*P* = 0.0002) and "Aorta" (*P* = 0.0002); and from domain Tissue Type MeSH: "Myocardium" (*P* = 0.0008) enriched with *NPPA*, *GATA4*, *AGT*, *ADRB1*, *NOS3*, *ACE* and *KCNJ11*. GeneGO identified an additional term "Cardiac Arrhythmias" (*P-FDR* = 3.2 x 10^−20^).

Protein-protein interactions and pathways enriched for BP genes {#sec006}
---------------------------------------------------------------

The protein-protein interactions (PPI) analyses showed that several novel gene proteins are important hubs in interaction with many other proteins. For example, *MAPKAPK2* (1q32.1, [Table 5](#pone.0198166.t005){ref-type="table"}) interacts among others with *BAG2*, *LISP1* and *ELAVL1*. *ELAVL1* interacts also with novel *XKR6* from 8p23.1 ([S16 Fig](#pone.0198166.s018){ref-type="supplementary-material"}). Of the novel genes *GRK5*, *MAPKAPK2*, *BLK*, *EFEMP2* and *ERCC6* ranked the highest in protein-protein interconnectivity (degree), while *MAPKAPK2*, *PINX1*, *EFEMP2*, *FAM167A* and *GRK5* were ranked the highest for important interconnections based on PageRank algorithm. Further, we entered the gene labels of the combined PPI network into the GeneGo software and found enrichment for *Cytoskeleton Remodeling/TGF/ Wnt* (*P*-FDR = 1.7 x 10^−17^), among other pathways.

Discussion {#sec007}
==========

This is the first large-scale study to systematically evaluate the role of joint effect of main gene and gene-alcohol interaction on BP in a very large meta-analysis across multiple ancestries.

BP genes interacting with alcohol show association with alcohol metabolism or dependence {#sec008}
----------------------------------------------------------------------------------------

The 8p23.1 containing novel BP associations spans \~3.3 Mb from *LOC107986913-SGK223* (8,452,998 bp) to *GATA4* (11,752,486 bp) (Tables [1](#pone.0198166.t001){ref-type="table"} and [2](#pone.0198166.t002){ref-type="table"}). Chromosome 8p23.1 is a complex region of deletions and replications, with repeated inverse structures\[[@pone.0198166.ref039], [@pone.0198166.ref040]\]. We identified four LD blocks in 8p23.1 ([Fig 1](#pone.0198166.g001){ref-type="fig"}). The significant GWAS results on 8p23.1 are from European ancestry participants in Stage 1, Stage 2 follow up, and combined Stage 1 and Stage 2 meta-analyses. For this region, the evidence of genetic associations was identified from all four BP traits at both current drinking and light/heavy drinking status (Tables [1](#pone.0198166.t001){ref-type="table"} and [2](#pone.0198166.t002){ref-type="table"}). The association on 8p23.1 found in the large European ancestry sample may also occur in other ancestries. The genome-wide significance levels in meta-analysis of European ancestry combined with African (5 genes), Asian (2 genes), and/or Hispanic (9 genes) ancestries have shown small improvements in their *P*-values compared to European ancestry meta-analysis alone (Tables [4](#pone.0198166.t004){ref-type="table"} and [S9](#pone.0198166.s029){ref-type="supplementary-material"}). For some of these associated SNVs on 8p23.1, the allele frequencies in European ancestry are higher than in African ancestry (e.g., rs4841294: 0.44 versus 0.25, respectively), and Hispanic Ancestry (e.g., rs34919878: 0.42 versus 0.25, respectively). These findings suggest the presence of cross-population association patterns between European, African, and Hispanic ancestries, although they are not genome-wide significant in African and Hispanic ancestries presumably because of small sample sizes.

![Identification of four independent LD blocks in the 8p23.1 region *(\~3*.*3 MBs*).](pone.0198166.g001){#pone.0198166.g001}

Several of the genes residing on 8p23.1 have been reported for alcohol metabolism and/or dependence. Overexpression of *PINX1* was reported to be associated with alcohol-related cirrhosis and fibrosis\[[@pone.0198166.ref041]\]. The transcription factor *GATA4* has been reported to be associated with alcohol dependence in several studies\[[@pone.0198166.ref042]--[@pone.0198166.ref045]\]. *GATA4* was suggested to regulate atrial natriuretic peptide (*ANP*, officially known as *NPPA*) modulating the amygdala's response to alcohol dependence\[[@pone.0198166.ref039]\] and is associated with BP\[[@pone.0198166.ref046]\]. In addition, a suggestive GWAS finding was observed between a variant near *BLK-LINC00208* with alcohol dependence\[[@pone.0198166.ref047]\]. The [S2 Note](#pone.0198166.s002){ref-type="supplementary-material"} provides a comprehensive summary of novel and neighboring genes and their potential biological relevance.

*FTO* (16q12.2) variants in interaction with alcohol consumption were significant for BP in European ancestry ([Table 2](#pone.0198166.t002){ref-type="table"}) and in combined meta-analysis of European and Asian ancestries ([Table 4](#pone.0198166.t004){ref-type="table"}). *FTO* is involved in the regulation of thermogenesis and the control of adipocyte differentiation into brown or white fat cells\[[@pone.0198166.ref048]\]. *FTO* variants have been associated in diverse ancestries with obesity-related traits\[[@pone.0198166.ref049], [@pone.0198166.ref050]\], as well as alcohol consumption and alcohol dependency\[[@pone.0198166.ref051], [@pone.0198166.ref052]\]. Frequency of alcohol consumption was suggested to modify the effect of *FTO* variants on body mass index\[[@pone.0198166.ref053]\].

*IL10* (interleukin 10, \~49 Kb upstream of rs3813963, [Table 5](#pone.0198166.t005){ref-type="table"}) has been associated with hypertension\[[@pone.0198166.ref054]\] and with alcoholic cirrhosis\[[@pone.0198166.ref055]\]. *MALAT1* (ncRNA, \~390 Kb upstream of rs201407003) is upregulated in the cerebellum, hippocampus and brain stem of alcoholics\[[@pone.0198166.ref056]\], which may represent an important mechanism for alcohol actions in the central nervous system.

It is worth to note that the allele frequencies for several potential SNVs in African ancestry ([Table 3](#pone.0198166.t003){ref-type="table"}) are low (\<0.10) but they are monomorphic in Europeans, which may suggest African-specific associations. Even though we did not have true replications for African ancestry associations (some of them due to missing SNVs or very low sample size in Stage 2), the identified candidate loci include genes previously related to alcohol consumption and dependence ([Table 3](#pone.0198166.t003){ref-type="table"}). *GABRB1*\[[@pone.0198166.ref057]\] (4p12) and *GABBR2*\[[@pone.0198166.ref058]\] (9q22.33, 143 kb upstream of rs73655199) are major neurotransmitters in the vertebrate brain, representing ligand-gated ion channels and have been shown to associate with alcohol dependence. *EYS* (6q12) displayed association with alcohol dependence in multi-ancestry population studies for rare\[[@pone.0198166.ref059]\] and common\[[@pone.0198166.ref060]\] variants. *LINGO2* (9p21.1) was reported to be associated with age at onset of alcohol dependence in the Collaborative Study on the Genetics of Alcoholism\[[@pone.0198166.ref016]\]. *ERCC6* (10q11.23) participates in DNA repair in response to oxidative stress\[[@pone.0198166.ref061]\]. Carriers of Arg1230Pro at *ERCC6* had a decreased risk for laryngeal cancer, strongest in heavy smokers and high alcohol consumers\[[@pone.0198166.ref062]\]. *CHAT* (10q11.23, 136 kb downstream of rs4253197) encodes an enzyme that catalyzes the biosynthesis of the neurotransmitter acetylcholine, and binge ethanol in adolescents was reported to decrease *CHAT* expression\[[@pone.0198166.ref063]\]. *BAG3* (10q26.11, 183 Kb downstream of rs201383951) was also suggested to contribute to alcohol-induced neurodegenerations\[[@pone.0198166.ref064]\]. A mouse study suggested that *BAG3* exerts a vaso-relaxing effect through the activation of the PI3K/Akt/eNOS signaling pathway, and may influence BP regulation\[[@pone.0198166.ref064]\]. A GWAS identified association of *BAG3* with dilated cardiomyopathy\[[@pone.0198166.ref065]\], and suggestive association with alcohol dependence\[[@pone.0198166.ref044]\]. *SGK1* (409 kb upstream of rs76987554) is associated with increased BP\[[@pone.0198166.ref066]\] and may contribute to the mechanisms underlying behavioral response to chronic ethanol exposure\[[@pone.0198166.ref067]\]. In addition, our two potential genes by alcohol interaction, *TARID* (rs76987554) and *CDH17* (rs115888294), have been recently reported association with BP in African ancestry, which supports our findings\[[@pone.0198166.ref068]\].

Regulatory features of BP genes {#sec009}
-------------------------------

Analysis of our significant BP variants for cis- transcription regulation via HaploReg\[[@pone.0198166.ref029]\] (S13 Table) showed that in total about 11% of variants were localized in promoter histone marks, 55% in enhancer histone marks, 34% at DNAse hypersensitive sites, 10% located at protein regulatory binding sites, and 88% were predicted to change regulatory protein binding motifs. These feature findings are inflated, because several variants are in LD blocks. Several of our variants had *P*-values ≤ 5.0 x 10^−8^ for being eQTLs for one or more target genes. The rs2921053 is the best eSNV regulating the transcription of *SGK223* in thyroid tissue (*P*-value = 1.04 x 10^−67^). Thyroid hormones are known to affect BP, heart and cardiovascular system\[[@pone.0198166.ref069]\].

Pathways enriched for BP genes {#sec010}
------------------------------

Our findings, *TNKS* ([Table 1](#pone.0198166.t001){ref-type="table"}), *FSTL5* and *MAPKAPK2* ([Table 5](#pone.0198166.t005){ref-type="table"}) and many other genes from PPI networks ([S17 Fig](#pone.0198166.s019){ref-type="supplementary-material"}), are part of *Wnt/beta-catenin*\[[@pone.0198166.ref070]\] signaling pathway. The *TNKS* forms a complex for degrading β-catenin (*CTNNB1*)\[[@pone.0198166.ref070]\] in interaction with *AXIN1*, *AXIN*2, and glycogen synthase kinase 3β (*GSK-3β*) ([S17](#pone.0198166.s019){ref-type="supplementary-material"} and [S18](#pone.0198166.s020){ref-type="supplementary-material"} Figs). The *Wnt/beta-catenin* pathway is known to be involved in renal injury and fibrosis induced by hypertension\[[@pone.0198166.ref071]\]. In addition, *TNKS* is involved in the regulation of *GLUT4* trafficking in adipocytes\[[@pone.0198166.ref072]\]. Other findings from correlated meta-analysis also contributed to pathways. For example, rs206648224 is intronic to *DYRK3*, 37 Kb upstream of *MAPKAPK2*, and 119 Kb downstream of *IL10*. *MAPKAPK2* is a stress-activated serine/threonine-protein kinase involved in cytokine production especially for *TNF* and *IL6*, and phosphorylates among others *LSP1*, already identified in association with BP\[[@pone.0198166.ref009]\]. *MAPKAPK2*\[[@pone.0198166.ref073]\] augments and *FSTL5*\[[@pone.0198166.ref074]\] diminishes the expression of Wnt/β-catenin signaling pathway.

Limitations {#sec011}
-----------

Despite large sample sizes in Stages 1 and 2 (≈131K individuals and ≈440K individuals, respectively), our novel variants (8p23 and 16q12) are common in their allele frequencies. For an analysis of gene by alcohol interactions in BP, even larger sample sizes are required to have sufficient power for detecting (and replicating) variants with lower allele frequency in the genome.

Our findings were based on a joint test of the main and interaction effects, which limits our ability to statistically differentiate the effect of interaction from the main effect. However, there is evidence that several of our novel and previously reported findings suggest association with alcohol consumption and dependency.

For African ancestry, the findings were not replicated, due to low sample size in Stage 2 (≈3K individuals) versus Stage 1 (≈21K individuals) and because seven potential variants for African ancestry were not available in Stage 2.

There are fewer associations of SNVs interacting with light/heavy drinkers compared to current drinkers, which is probably due to the reduced sample size in light/heavy drinkers. We also found an association in light/heavy drinkers which is not present in current drinkers. The *LOC105374235* gene interacts with light/heavy drinkers for SBP but does not interact with current drinkers for SBP in African ancestry ([Table 3](#pone.0198166.t003){ref-type="table"} and [S10 Fig](#pone.0198166.s012){ref-type="supplementary-material"}). These findings suggest that novel loci for BP can be expected to be discovered when increasing the sample size for light/heavy drinkers.

The two Brazilian cohorts (from discovery only) were included in the multi-ancestry meta-analyses. However, their association results did not contribute to SNV-alcohol interactions for BP traits, which could be in part to the relative small sample size (4,415 subjects) affecting the power of associations in the joint gene-environmental interaction model.

Conclusion {#sec012}
----------

We identified and replicated five novel loci (380 SNVs in 21 genes) via joint test of main genetic effect and gene-alcohol interaction, and eight novel loci (11 genes) using correlated meta-analysis in European ancestry. We also found 18 potentially novel BP loci in discovery (*P* ≤ 5.0 x 10^−8^) in gene-alcohol interaction model in African ancestry participants, but without replication. In addition, we identified 49 loci previously reported for BP (2,159 SNVs in 109 genes) using the joint test for interaction in European and multi-ancestries meta-analyses. Several of these SNVs/genes are related to alcohol metabolism and dependence, have evidence for regulatory features, and are enriched in pathways for cardiovascular disease, hypertension and blood pressure homeostasis. Our findings provide novel insights into mechanisms of BP regulation and may highlight new therapeutic targets.

Methods {#sec013}
=======

Individuals between the ages of 18--80, who participated in the studies, provided written informed consent and approval by their research ethics committees and/or institutional review boards. The description of each participating study cohort is shown in [S1 Note](#pone.0198166.s001){ref-type="supplementary-material"}.

Phenotypes, alcohol consumption, and study cohorts {#sec014}
--------------------------------------------------

SBP (in mmHg) and diastolic BP (DBP in mmHg) were measured at resting or sitting positions by averaging up to three BP readings at the same clinical visit. To account for the reduction in BP levels due to anti-hypertensive medication use, the BP levels were adjusted by adding 15 mm Hg to SBP and 10 mm Hg to DBP values. After adjustment, mean arterial pressure (MAP) was defined as the sum of two-thirds of DBP and one-third of SBP, and pulse pressure (PP) was estimated as the difference between SBP and DBP. Hypertension was defined whether participants presented: (i) SBP ≥ 140 mm Hg, (ii) DBP ≥ 90 mm Hg, and/or (iii) taking anti-hypertensive medication. For quality control (QC), SE-N (*i*.*e*., inverse of the median standard error versus the square root of the sample size) plots were produced\[[@pone.0198166.ref075]\]. If cohort-specific analytical problems existed, they were corrected.

Definition of "a dose or a drink" is about 17.7 grams of ethanol, which is the amount of a typical beverage of 12 oz. (354.882 ml) bottle or can of beer, a 5 oz. (147.868 ml) glass of wine, or a standard 1.5 oz. (44.3603 ml) shot of 80-proof spirits, such as gin, vodka, or whiskey\[[@pone.0198166.ref076]\]. Alcohol consumption was defined by two categories: (I) as current drinking (yes/no), and (II) in the subset of drinkers, as light/heavy drinking (1--7 drinks/week or ≥8 drinks/week).

Genotyping {#sec015}
----------

Genotyping was performed using Illumina (San Diego, CA, USA) or Affymetrix (Santa Clara, CA, USA) arrays. 1000 Genomes Imputation was implemented using MACH and Minimac, IMPUTE2, and/or BEAGLE software, based on the cosmopolitan panel from Phase I Integrated Release Version 3 Haplotypes (2010--11 data freeze, 2012-03-14 haplotypes). Dosages from 1000 Genomes were used in 106 cohorts out of 115 Stage 1 and Stage 2 cohorts. If 1000 Genomes were not available in a cohort, dosages based on HapMap Phase II / III reference panel (2 Stage 1 cohorts and 4 Stage 2 cohorts) or genotyped data (3 Stage 2 cohorts) were used in the analyses. Information of study characteristics, genotyping, imputation, covariates, and analyses are summarized for Stage 1 in [S1](#pone.0198166.s021){ref-type="supplementary-material"}--[S4](#pone.0198166.s024){ref-type="supplementary-material"} Tables, and for Stage 2 in [S5](#pone.0198166.s025){ref-type="supplementary-material"}--[S8](#pone.0198166.s028){ref-type="supplementary-material"} Tables.

Interaction association analysis {#sec016}
--------------------------------

Each Stage 1 and Stage 2 cohort conducted a joint statistical model analysis\[[@pone.0198166.ref024]\]: $$E\left( Y \right) = b_{0} + b_{G}SNV + ~b_{E}E + ~b_{GE}SNV*E + b_{C}C,$$

where *SNV* is the dosage of the genetic (*G*) variant, *E* is the alcohol consumption (current drinker or light/heavy drinker) effect, *SNV*\**E* is SNV-alcohol interaction effect, *b* values are the respective beta coefficients from regression analysis and *C* represents covariates (age, sex, principal components (PCs), and other study-specific covariates). The joint model provides estimates of *b*~*G*~ and *b*~*GE*~, robust estimates of the corresponding standard errors (SEs) and covariance, and *P*-values from the joint 2 degree-of-freedom Wald test. The *SNV* effect (*b*~*G*~) is context-dependent and thus should not be interpreted as the "main effect"\[[@pone.0198166.ref023]\]. Principal components were derived from genotyped SNVs and used for controlling population stratification and genomic confounding effects. Each cohort decided the number of PCs to be included in the joint statistical model analysis, as shown in [S4 Table](#pone.0198166.s024){ref-type="supplementary-material"} (Discovery, in Stage 1) and [S8 Table](#pone.0198166.s028){ref-type="supplementary-material"} (Replication, in Stage 2). Particularly for African ancestry, it was required to include at the least the first PC and additional PCs as appropriate.

The association analyses were implemented by programming in R or using ProbABEL\[[@pone.0198166.ref077]\] for studies of unrelated individuals, or by GenABEL/MixABEL\[[@pone.0198166.ref078]\] or MMAP (O'Connell, unpublished; personal communication), which account for family relatedness.

Meta-analysis and quality control {#sec017}
---------------------------------

We employed a modified METAL software\[[@pone.0198166.ref024]\] to perform 2 degrees of freedom joint meta-analysis, using the inverse-variance weighted fixed-effects approach. We applied multiple steps of QC, both at cohort association analysis and at meta-analysis level, implemented with EasyQC, an R package\[[@pone.0198166.ref075]\]. They included filtering of markers with imputation quality \< 0.5; with minor allele frequency \< 1%; minor allele count ≤ 10; if alleles were mismatched when comparing the cohort's alleles with the 1000 Genomes cosmopolitan panel; and/or if the allele frequencies were different from those of the 1000 Genomes. In addition, a cohort participated in the meta-analysis if it had more than 50 individuals consuming alcohol. The meta-analysis results were reported if they had more than 5,000 individuals and if at least two studies for each SNV contributed to the analysis. Markers with meta-heterogeneity *P* \< 1.0 x 10^−6^ were dropped. We used (double) study- and meta- level genomic control corrections to account for population stratification accumulated across studies or due to unaccounted relatedness. Distributions of--log~10~ *P*-values of observed versus--log~10~ *P*-values expected (QQ plots) are shown in [S2](#pone.0198166.s004){ref-type="supplementary-material"} and [S3](#pone.0198166.s005){ref-type="supplementary-material"} Figs.

Correlated meta-analysis {#sec018}
------------------------

The genome (millions of SNPs) are under the null hypothesis of no genotype-phenotype association, which is only mildly contaminated with a relatively smaller set of SNVs that are under the alternative. The correlated meta-analysis\[[@pone.0198166.ref025], [@pone.0198166.ref026]\] performs a large sampling of genome and produces the polychoric correlation estimator (using SAS PROC FREQ). The estimator measures the relation degree of any non-independence between scans. The correlated meta-analysis corrects the inference for it, retaining the proper type I error structure. The correlated meta-analysis\[[@pone.0198166.ref025], [@pone.0198166.ref026]\] uses the Fisher's 1925 method by combining *P*-values at each location of the genome. This technique uses the fact that for number of scans, sum of −2 ln (*p*~*i*~), approximately chi-square (*X*^2^) with two degrees of freedom. In the case of correlated GWAS, this sum is no longer distributed as a simple *X*^2^. Instead, the correlated meta-analysis method\[[@pone.0198166.ref025], [@pone.0198166.ref026]\] uses an inverse-normal transform, *Z*~i~ = *θ*^−1^ (*p*~*i*~) forming the N dimensional vector Z of all *Z*~i~ s. Then, the method applies the basic theorem of multidimensional statistics for the matrix D, if *Z\~N*(*O*, *E*) then *DZ\~N*(*O*, *E*∑*D*'). In particular, when *D* is a 1×*N* vector of all 1's, *SUM*(*Z*) = *D Z \~ N*(0, *SUM*(∑)), whose tail probability gives the *Z* meta-analysis *P*-value. In this case, for estimating ∑, the SNV *P*-values are dichotomized across the genome as (*P* ≤ 0.5; *P* \> 0.5). The software was developed in SAS.

Bioinformatics analyses {#sec019}
-----------------------

The annotation of variants was sourced from NCBI dbSNP build 138 (hg19) during the analyses and updated to dbSNP build 150 (hg38) for reporting results. Our candidate SNVs for BP were questioned if they resided in any of regulatory marks, analyzing information from the NCBI Entrez gene, dbSNP, Encyclopedia of DNA Elements Consortium (ENCODE) project and the Roadmap Epigenomics Mapping Consortium (ROADMAP), as summarized by HaploReg\[[@pone.0198166.ref028], [@pone.0198166.ref029]\], and RegulomeDB\[[@pone.0198166.ref030], [@pone.0198166.ref031]\].

HaploReg (v.4.1) queries were used to identify functional annotations including the chromatin state segmentation on the Roadmap reference epigenomes, conserved regions by GERP and SiPhy, the experiments of DNAse hypersensitivity and ChIP-seq experiments from ENCODE. UCSC Genome Browser and GENCODE were used for gene annotations. We calculated the proximity of each variant to a gene.

RegulomeDB (v. 1.1, accessed on 06.15.2017) provided regulatory information of gene expression via ChIP factors, DNase sensitivity, and transcription factor (TF) binding sites from ENCODE. RegulomeDB uses the Position-Weight Matrix for TF binding, and databases JASPAR CORE, TRANSFAC and UniPROBE\[[@pone.0198166.ref079]\]. RegulomeDB reported Chromatin States from ROADMAP, eQTLs from several tissue types, DNase footprinting\[[@pone.0198166.ref080], [@pone.0198166.ref081]\], differentially methylated regions\[[@pone.0198166.ref082]\], manually curated regions and validated functional SNVs.

GWAS3D\[[@pone.0198166.ref033]\] (accessed on 03.15.2017) was used to analyze genetic variants that may affect regulatory elements, by integrating annotations from cell type-specific chromatin states, epigenetic modifications, sequence motifs and cross-species conservation. The regulatory elements are inferred from the genome-wide chromosome interaction data, chromatin marks in different cell types measured by high-throughput chromosome conformation capture technologies (5C, ChIA-PET and Hi-C) from ENCODE, Gene Expression Omnibus (GEO) database, published resources and regulatory factor motifs. We gathered also evidence for eQTLs based on GTEx (v. 7), GRASP software and special gene expression reported results\[[@pone.0198166.ref083], [@pone.0198166.ref084]\].

The importance of our novel and potential novel BP genes (Tables [1](#pone.0198166.t001){ref-type="table"}--[5](#pone.0198166.t005){ref-type="table"}) were mined by means of four methods: enrichment analysis, protein- protein interactions (PPI), analytical gene expression cis-regulation, and analytical gene expression trans-regulation.

The GeneGO and Literature Lab of ACUMENTA software (accessed on 03.15. 2017) were used for enrichment analysis. We tested if novel genes were significantly enriched among pre-specified gene sets defined in pathways, or by shared roles in particular diseases or biological processes from Gene Ontology. The GeneGO enrichment analysis consists of matching unique gene symbols of possible targets for the \"common\", \"similar\" and \"unique\" sets with gene symbols in functional ontologies. The probability of a random intersection between a set of gene symbols, the size of target list with ontology entities, is estimated by *P*-value of a hypergeometric intersection. The lower *P*-value means higher relevance of the entity to the dataset, which shows in higher rating for the entity.

Literature Lab is an interface between experimentally-derived gene lists and scientific literature in a curated vocabulary of 24,000 biological and biochemical terms. It employs statistical and clustering analysis on over 17.5 million PubMed abstracts (from 01.01.1990 to the present) to identify pathways (809 pathways), diseases, compounds, cell biology and other areas of biology and biochemistry. The analysis engine compares statistically the submitted gene set to 1,000 random gene sets generated in the analysis to identify term relationships that are associated with the gene set more than by chance alone.

The BP candidate genes were assessed via PPI of databases from Biological General Repository for Interaction Datasets (BioGrid), Escherichia coli K-12 (EcoCyc), and Human Protein Database (HPRD) as summarized by the National Center for Biotechnology Information (NCBI, accessed on 02.28.2017). The gene list from PPI was evaluated using igraph package\[[@pone.0198166.ref085]\]. The network was built using our programs in SAS, to a Pajek format and imported into igraph in R language. "Google" PageRank algorithm provided the importance of genes (website pages) in a network, which was implemented by igraph.

Information of data analysis tools and databases, including their website links (when available) and the corresponding literature citations, are provided in [S15 Table](#pone.0198166.s035){ref-type="supplementary-material"}.

Supporting information {#sec020}
======================

###### Description of participating studies.

Study descriptions of discovery cohorts (Stage 1) and replication cohorts (Stage 2).

(DOCX)

###### 

Click here for additional data file.

###### Summary of biological description for novel BP loci.

Information summary of the nearest genes for blood pressure novel loci.

(DOCX)

###### 

Click here for additional data file.

###### Study design of SNV x alcohol interactions for BP.

Schematic study design of the joint model of SNV main effect and SNV-alcohol consumption interaction; Blood pressure (BP) traits: systolic BP (SBP), diastolic BP (DBP), mean arterial pressure (MAP), and pulse pressure (PP); Alcohol consumption was defined by two categories: (I) as current drinking (yes/no), and (II), in the subset of drinkers, as light/heavy drinking (1--7 drinks/week or ≥8 drinks/week); Meta-analysis using a modified version of METAL: Stage 1 (discovery), Stage 2 (replication) and combined Stage 1 and Stage 2; Cohorts: European ancestry (EA), African ancestry, Asian ancestry (ASA), Hispanic ancestry (HA), Brazilian (BRA); Correlated meta-analysis in EA for four BP traits; Number of BP loci (genes), novel and reported.

(TIF)

###### 

Click here for additional data file.

###### QQ plots for BP traits for current drinkers.

Meta-analysis distributions of--log~10~ *P*-values of observed versus--log~10~ *P*-values expected (QQ plots) for current drinkers (yes/no) European ancestry (A) and in African ancestry (B).

(TIF)

###### 

Click here for additional data file.

###### QQ plots for BP traits for light/heavy drinkers.

Meta-analysis distributions of--log~10~ *P*-values of observed versus--log~10~ *P*-values expected (QQ plots) for light/heavy drinkers (1--7 drinks/week or ≥8 drinks/week) in European ancestry (A) and in African ancestry (B).

(TIF)

###### 

Click here for additional data file.

###### Regional association plots on 8p23.

SNV x current drinker interaction for SBP (A), DBP (B), MAP (C) and PP (D) in European Ancestry; four linkage disequilibrium (LD) blocks (see also [Fig 1](#pone.0198166.g001){ref-type="fig"}).

(TIF)

###### 

Click here for additional data file.

###### Regional association plots on 16q12.

SNV x current drinker interaction for SBP (A), DBP (B), MAP (C) and PP (D) in European Ancestry.

(TIF)

###### 

Click here for additional data file.

###### 

**Manhattan plots of combined Stage 1 and Stage 2 meta-analysis for SBP in current drinkers (A) and in light/heavy drinkers (B) in European ancestry**. Novel loci are highlighted in blue.

(TIF)

###### 

Click here for additional data file.

###### 

**Manhattan plots of combined Stage 1 and Stage 2 meta-analysis for DBP in current drinkers (A) and in light/heavy drinkers (B) in European ancestry**. Novel loci are highlighted in blue.

(TIF)

###### 

Click here for additional data file.

###### 

**Manhattan plots of combined Stage 1 and Stage 2 meta-analysis for MAP in current drinkers (A) and in light/heavy drinkers (B) in European ancestry**. Novel loci are highlighted in blue.

(TIF)

###### 

Click here for additional data file.

###### 

**Manhattan plots of combined Stage 1 and Stage 2 meta-analysis for PP in current drinkers (A) and in light/heavy drinkers (B) in European ancestry**. Novel loci are highlighted in blue.

(TIF)

###### 

Click here for additional data file.

###### 

**Manhattan plots of combined Stage 1 and Stage 2 meta-analysis for SBP in current drinkers (A) and in light/heavy drinkers (B) in African ancestry**. Novel loci are highlighted in blue.

(TIF)

###### 

Click here for additional data file.

###### 

**Manhattan plots of combined Stage 1 and Stage 2 meta-analysis for DBP in current drinkers (A) and in light/heavy drinkers (B) in African ancestry**.

(TIF)

###### 

Click here for additional data file.

###### 

**Manhattan plots of combined Stage 1 and Stage 2 meta-analysis for MAP in current drinkers (A) and in light/heavy drinkers (B) in African ancestry**.

(TIF)

###### 

Click here for additional data file.

###### 

**Manhattan plots of combined Stage 1 and Stage 2 meta-analysis for PP in current drinkers (A) and in light/heavy drinkers (B) in African ancestry**. Novel loci are highlighted in blue.

(TIF)

###### 

Click here for additional data file.

###### 

**Manhattan plots of combined Stage 1 and Stage 2 meta-analysis for SBP (A) and DBP (B) in current drinkers in Asian ancestry**.

(TIF)

###### 

Click here for additional data file.

###### 

**Manhattan plots of combined Stage 1 and Stage 2 meta-analysis for MAP (A) and PP (B) in current drinkers in Asian ancestry**.

(TIF)

###### 

Click here for additional data file.

###### Protein-protein interactions network.

In the figure, ellipses in black represent all novel genes; ellipses in red represent novel from EA; squares in blue represent potential novel findings from African ancestry; and triangles in black from correlated-meta. Labeled with A and B free-hand circles are proteins that have two connections, while labeled within C are proteins that have three-five connections with our findings. *APP* interacts with five of our BP candidate novel genes *TTLL7*, *SOX7*, *PINX1*, *LINGO2* and *KCNMB2* (circle C).

(TIF)

###### 

Click here for additional data file.

###### Protein-protein interactions between tankyrase and beta-catenin.

Tankyrase (from *TNKS* gene) and β-catenin (from *CTNNB1* gene).

(TIF)

###### 

Click here for additional data file.

###### *Wnt* signaling KEGG pathway.

*TNKS* interacts with *CTNNB1*.

(TIF)

###### 

Click here for additional data file.

###### Descriptive analyses for discovery data (Stage 1) in current drinkers.

Characteristics of blood pressure (BP) in current drinkers (yes or no), within sub-sample of individuals with or without anti-hypertensive (BP Lowering) medications, and in combined samples; SBP, systolic BP; DBP, diastolic BP; MAP, mean arterial pressure; PP, pulse pressure; N, number of individuals; mean, mean levels; SD, standard deviation of mean; Min, minimum value; Max, maximum value; For each BP trait (SBP, DBP, MAP, and PP), the extreme BP values were winsorised if a BP value was greater than 6 SD, above or below the mean, setting the BP value exactly at 6 SDs from the mean.

(XLSX)

###### 

Click here for additional data file.

###### Descriptive analyses for discovery data (Stage 1) in light/heavy drinkers.

Characteristics of blood pressure (BP) in light/heavy drinkers (1--7 drinks/week or ≥8 drinks/week), within sub-sample of individuals with or without anti-hypertensive (BP Lowering) medications, and in combined samples; SBP, systolic BP; DBP, diastolic BP; MAP, mean arterial pressure; PP, pulse pressure; N, number of individuals; mean, mean levels; SD, standard deviation of mean; Min, minimum value; Max, maximum value; For each BP trait (SBP, DBP, MAP, and PP), the extreme BP values were winsorised if a BP value was greater than 6 SD, above or below the mean, setting the BP value exactly at 6 SDs from the mean.

(XLSX)

###### 

Click here for additional data file.

###### Descriptive analyses for blood pressure (BP) stratified by alcohol consumption for discovery data (Stage 1).

Characteristics of systolic BP and diastolic BP, after correcting for BP lowering medication and winsorizing observations.

(XLSX)

###### 

Click here for additional data file.

###### Characteristics of each study and their genotype data for discovery data (Stage 1).

Study design, population-based or cohort-unrelated; Principal components used; Other covariates entered in the model; Genotyping platforms; Genotyping calling algorithm; Quality Control Filters; Imputation reference panel; Number of SNVs (single nucleotide variants).

(XLSX)

###### 

Click here for additional data file.

###### Descriptive analyses for replication data (Stage 2) in current drinkers.

Characteristics of blood pressure (BP) within current drinkers (CURD: yes or no), and in alcohol combined samples; SBP, systolic BP; DBP, diastolic BP; MAP, mean arterial pressure; PP, pulse pressure; N, number of individuals; mean, mean levels; SD, standard deviation of mean; Min, minimum value; Max, maximum value.

(XLSX)

###### 

Click here for additional data file.

###### Descriptive analyses for replication data (Stage 2) in light/heavy drinkers.

Characteristics of blood pressure (BP) within light/heavy drinkers (LHD: 1--7 drinks/week or ≥8 drinks/week), and in alcohol combined samples; SBP, systolic BP; DBP, diastolic BP; MAP, mean arterial pressure; PP, pulse pressure; N, number of individuals; mean, mean levels; SD, standard deviation of mean; Min, minimum value; Max, maximum value.

(XLSX)

###### 

Click here for additional data file.

###### Demographic statistics for replication data (Stage 2).

N, Number of subjects; % Hypertensive, defined whether participants presented: (i) SBP ≥ 140 mm Hg, (ii) DBP ≥ 90 mm Hg, and/or (iii) taking anti-hypertensive medication; Mean, age mean; SD, standard deviation of mean; Min, minimum age; Max, maximum age.

(XLSX)

###### 

Click here for additional data file.

###### Characteristics of each study and their genotype data for replication data (Stage 2).

Study design, population-based or cohort-unrelated; Principal components used; Other covariates entered in the model; Genotyping platforms; Genotyping calling algorithm; Imputation reference panel; NCBI dbSNP build; Analysis software; Robust or model-based statistics; Family studies: Method of handling relatedness.

(XLSX)

###### 

Click here for additional data file.

###### Novel SNVs/ genes associated with BP traits in multi-ancestry and specific-ancestry meta-combined results.

Top significant associated SNVs are shown per gene for each trait and alcohol exposure.

(XLSX)

###### 

Click here for additional data file.

###### SNVs/genes associated with BP traits in European ancestry.

Variants previously reported for blood pressure (BP) in genome-wide association studies. The most significant associated SNVs are shown per gene for each Blood Pressure (BP) trait and alcohol status. Abbreviations: Nb, order number based on genes; SNV, single nucleotide variant; Chr, chromosome; Position, Gene, and Role in dbSNP build 150 (hg38) annotation; Role: Intronic, missense, up-stream or downstream, or intergenic (blank space) SNV; Near gene reflects genes at up to +/-500 kb and related to BP / alcohol; A1/2, Coded and non-coded alleles; Frq1, Frequency of coded allele; Trait, SBP: Systolic BP, DBP: Diastolic BP, MAP: Mean Arterial Pressure, PP: Pulse Pressure; Drink: Alcohol consumption, CURD, Current drinker (yes/no), LHD, Light(1--7 drinks/week) or heavy (≥8 drinks/week) drinker; Stage 1, Discovery cohorts; Stage 2, Replication cohorts; Stage 1 & Stage 2, Discovery and Replication combined; b_M(S.E.), beta coefficient of SNV (standard error); b_I(S.E.): SNV\*E is SNV-alcohol interaction effect (standard error); *P*-Value: modified-interaction METAL *P*-Value; N, Number of subjects; *P*-Meta, *P*-Meta, modified-interaction METAL *P*-Value of Meta-analysis in combined Stage 1 and Stage 2; Het-P value, Heterogeneity *P*-Value. \* These genes were detected also via correlated meta-analysis.

(XLSX)

###### 

Click here for additional data file.

###### SNVs/genes associated with BP traits in African ancestry.

Variants previously reported for blood pressure (BP) in genome-wide association studies. The most significant associated SNVs are shown per gene for each Blood Pressure (BP) trait and alcohol status. Abbreviations: Nb, order number based on genes; SNV, single nucleotide variant; Chr, chromosome; Position, Gene, and Role in dbSNP build 150 (hg38) annotation; Role: Intronic or intergenic (blank space) SNV; Near gene reflects genes at up to +/-500 kb and related to BP / alcohol; A1/2, Coded and non-coded alleles; Frq1, Frequency of coded allele; Trait, SBP: Systolic BP, DBP: Diastolic BP, MAP: Mean Arterial Pressure, PP: Pulse Pressure; Drink: Alcohol consumption, CURD, Current drinker (yes/no); Stage 1, Discovery cohorts; Stage 2, Replication cohorts; Stage 1 & Stage 2, Discovery and Replication combined; b_M(S.E.), beta coefficient of SNV (standard error); b_I(S.E.): SNV\*E is SNV-alcohol interaction effect (standard error); *P*-Value: modified-interaction METAL *P*-Value; N, Number of subjects; *P*-Meta, *P*-Meta, modified-interaction METAL *P*-Value of Meta-analysis in combined Stage 1 and Stage 2; Het-P value, Heterogeneity *P*-Value. \* These genes were detected also via correlated meta-analysis.

(XLSX)

###### 

Click here for additional data file.

###### SNVs/genes associated with BP traits in multi-ancestry meta-analysis in combined Stage 1 and Stage 2.

Variants previously reported for blood pressure (BP) in genome-wide association studies. The most significant associated SNVs are shown per gene for each Blood Pressure (BP) trait and alcohol status. Abbreviations: Nb, order number based on genes; SNV, single nucleotide variant; Chr, chromosome; Position, Gene, and Role in dbSNP build 150 (hg38) annotation; Role: Intronic, missense, up-stream or downstream, or intergenic (blank space) SNV; Near gene reflects genes at up to +/-500 kb and related to BP / alcohol; A1/2, Coded and non-coded alleles; Frq1, Frequency of coded allele; Ancestry, EA: European Ancestry, AA: African American Ancestry, ASA: Asian American Ancestry, HA: Hispanic Ancestry; Trait, SBP: Systolic BP, DBP: Diastolic BP, MAP: Mean Arterial Pressure, PP: Pulse Pressure; Drink: Alcohol consumption, CURD, Current drinker (yes/no), LHD, Light(1--7 drinks/week) or heavy (≥8 drinks/week) drinker; Stage 1 and Stage 2, Combined Discovery and Replication; b_M, beta coefficient of SNV; b_I: SNV\*E is SNV-alcohol interaction effect; *P*-Value, modified-interaction METAL *P*-Value of meta-analysis in combined Stage 1 and Stage 2; N, Number of subjects; Het-P value, Heterogeneity *P*-Value.

(XLSX)

###### 

Click here for additional data file.

###### SNVs/genes associated with BP traits for regulatory features using HaploReg and RegulomeDB.

Association findings from European Ancestry (novel), African Ancestry (potential) and correlated meta-analysis (novel variants). The annotation of variants was sourced from NCBI dbSNP build 138 (hg19) during the analyses and updated to dbSNP build 150 (hg38) for reporting results. Abbreviations: Nb, order number based on SNVs; Position, dbSNP build 150 (hg38) annotation; Variant, single nucleotide variant (SNV); Ref, reference allele; Alt, alternative allele; AFR Freq, Freq of Ref in African ancestry; ASN Freq, Freq of Ref in East Asian ancestry; EUR Freq, Freq of Ref in European ancestry; GERP cons and Siphy cons, measured conserved regions. RegulomeDB scoring has classes defined as 1b, 1d and 1f: likely to affect binding and linked to expression of a gene target, with details: 1b (eQTL + TF binding + any motif + DNase footprint + DNase peak); 1d (eQTL + TF binding + any motif + DNase peak); 1f (eQTL + TF binding/DNase peak), 2a and 2b: likely to affect binding, 3a: less likely to affect binding, 4, 5, and 6: minimal binding evidence, and 7: no data. This software was accessed on 06.15.2017. Regulatory function measured by Promoter histone marks, Enhancer histone marks, DNase (DNAse hypersensitivity), Proteins bound, Motifs changed.

(XLSX)

###### 

Click here for additional data file.

###### Novel SNVs/genes associated with BP traits for eSNV/eQTL using GTEx.

Target genes (Tissues and *P*-Values). Association findings from European Ancestry (novel) and correlated meta-analysis (novel variants). The annotation of variants was sourced from NCBI dbSNP build 138 (hg19) during the analyses and updated to dbSNP build 150 (hg38) for reporting results. Abbreviations: Nb, order number based on SNVs; Position, dbSNP build 150 (hg38) annotation; Variant, single nucleotide variant (SNV); Ref, reference allele; Alt, alternative allele; AFR Freq, Freq of Ref in African ancestry; ASN Freq, Freq of Ref in East Asian ancestry; EUR Freq, Freq of Ref in European ancestry. \* RegulomeDB scoring has classes defined as 1b, 1d and 1f: likely to affect binding and linked to expression of a gene target, with details: 1b (eQTL + TF binding + any motif + DNase footprint + DNase peak); 1d (eQTL + TF binding + any motif + DNase peak); 1f (eQTL + TF binding/DNase peak), 2a and 2b: likely to affect binding, 3a: less likely to affect binding, 4, 5, and 6: minimal binding evidence, and 7: no data. This software was accessed on 06.15.2017. Regulatory function measured by Promoter histone marks, Enhancer histone marks, DNase (DNAse hypersensitivity), Proteins bound, Motifs changed.

(XLSX)

###### 

Click here for additional data file.

###### Data analysis tools and databases.

(DOCX)

###### 

Click here for additional data file.
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